CA1220424A - Parenteral formulation of nimodipine, a process for its preparation and its use for controlling diseases - Google Patents

Parenteral formulation of nimodipine, a process for its preparation and its use for controlling diseases

Info

Publication number
CA1220424A
CA1220424A CA000453627A CA453627A CA1220424A CA 1220424 A CA1220424 A CA 1220424A CA 000453627 A CA000453627 A CA 000453627A CA 453627 A CA453627 A CA 453627A CA 1220424 A CA1220424 A CA 1220424A
Authority
CA
Canada
Prior art keywords
weight
parenteral formulation
polyethylene glycol
solvent
nimodipine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000453627A
Other languages
English (en)
French (fr)
Inventor
Dieter Hoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of CA1220424A publication Critical patent/CA1220424A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
CA000453627A 1983-05-06 1984-05-04 Parenteral formulation of nimodipine, a process for its preparation and its use for controlling diseases Expired CA1220424A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3316510.6 1983-05-06
DE19833316510 DE3316510A1 (de) 1983-05-06 1983-05-06 Parenterale formulierung von nimodipin, ein verfahren zu ihrer herstellung sowie ihre verwendung bei der bekaempfung von erkrankungen

Publications (1)

Publication Number Publication Date
CA1220424A true CA1220424A (en) 1987-04-14

Family

ID=6198265

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000453627A Expired CA1220424A (en) 1983-05-06 1984-05-04 Parenteral formulation of nimodipine, a process for its preparation and its use for controlling diseases

Country Status (19)

Country Link
US (1) US5114956A (cg-RX-API-DMAC7.html)
EP (1) EP0126315B1 (cg-RX-API-DMAC7.html)
JP (1) JPS59206305A (cg-RX-API-DMAC7.html)
KR (1) KR920000306B1 (cg-RX-API-DMAC7.html)
AT (1) ATE24835T1 (cg-RX-API-DMAC7.html)
AU (1) AU562293B2 (cg-RX-API-DMAC7.html)
BE (1) BE899564A (cg-RX-API-DMAC7.html)
CA (1) CA1220424A (cg-RX-API-DMAC7.html)
DE (2) DE3316510A1 (cg-RX-API-DMAC7.html)
DK (1) DK164148C (cg-RX-API-DMAC7.html)
ES (1) ES531995A0 (cg-RX-API-DMAC7.html)
FR (1) FR2545354B1 (cg-RX-API-DMAC7.html)
GR (1) GR81609B (cg-RX-API-DMAC7.html)
HK (1) HK75889A (cg-RX-API-DMAC7.html)
IL (1) IL71744A (cg-RX-API-DMAC7.html)
IT (1) IT1181804B (cg-RX-API-DMAC7.html)
PT (1) PT78542B (cg-RX-API-DMAC7.html)
SG (1) SG44489G (cg-RX-API-DMAC7.html)
ZA (1) ZA843352B (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60246313A (ja) * 1984-05-22 1985-12-06 Yamanouchi Pharmaceut Co Ltd 塩酸ニカルジピンの注射剤およびその製法
FR2585574B1 (fr) * 1985-07-31 1988-09-09 Corbiere Jerome Nouvelles compositions pharmaceutiques anti-glaucomateuses a base de 1,4-dihydropyridines et leur procede d'obtention
AT387518B (de) * 1985-12-18 1989-02-10 Bayer Ag Verfahren zur herstellung von fluessigen spruehpraeparaten von dihydropyridinen
DE3544692A1 (de) * 1985-12-18 1987-06-19 Bayer Ag Dihydropyridinspray, verfahren zu seiner herstellung und seine pharmazeutische verwendung
DE3702105A1 (de) * 1987-01-24 1988-08-04 Bayer Ag Parenterale loesung
GB2228412B (en) * 1989-02-28 1993-04-14 Syntex Inc Nicardipine pharmaceutical composition for parenteral administration
RU1804845C (ru) * 1991-02-15 1993-03-30 Институт Органического Синтеза Латвийской Ан Ноотропное вещество
KR100517210B1 (ko) * 1994-12-12 2006-06-07 오메로스 코포레이션 통증,염증및경련억제용관주용액
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
RU2180852C2 (ru) * 1994-12-12 2002-03-27 Омерос Медикл Системс, Инк. Ингибирующий раствор и способ подавления боли, воспаления или спазма
AU4467396A (en) 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
US6413961B1 (en) 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
US6136799A (en) * 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations
DE10142417A1 (de) * 2001-08-31 2003-03-20 Molecular And Clinical Drug Re Arzneimittel
DE10142416A1 (de) * 2001-08-31 2003-03-20 Molecular And Clinical Drug Re Verfahren zur Herstellung von Lösungen
US8034762B2 (en) * 2004-09-02 2011-10-11 Cognosci, Inc. Treatment of subarachnoid hemorrhage with Apo E analogs
EP1933837A4 (en) * 2005-10-14 2009-07-15 Transform Pharmaceuticals Inc PHARMACEUTICAL LIQUID COMPOSITIONS OF NIMODIPIN
EP2015730A1 (de) * 2006-04-28 2009-01-21 Basf Se Verfahren zur solubilisierung von hydrophoben wirkstoffen in wässrigem medium
US8728504B2 (en) 2010-02-05 2014-05-20 Basf Se Process for solubilizing hydrophobic active ingredients in aqueous medium
EP2531548A1 (de) 2010-02-05 2012-12-12 Basf Se Verfahren zur solubilisierung von hydrophoben wirkstoffen in wässrigem medium
AU2012250050B2 (en) 2011-04-28 2017-04-06 Platform Brightworks Two, Ltd. Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
US10092553B2 (en) 2016-04-13 2018-10-09 Nortic Holdings Inc. Stable nimodipine parenteral formulation
CN114886850A (zh) * 2016-04-13 2022-08-12 格雷斯疗法公司 尼莫地平制剂及治疗病症的方法
EP3755326A4 (en) 2018-02-22 2021-11-03 Nortic Holdings Inc. STABLE PARENTERAL FORMULATION OF NIMODIPINE
US12414943B2 (en) 2022-05-16 2025-09-16 Grace Therapeutics U.S., Inc. Nimodipine parenteral administration
CN117502433A (zh) * 2023-11-08 2024-02-06 中国科学院海洋研究所 一种水母刺丝囊存放保护剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2117571C3 (de) * 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
US4154839A (en) * 1975-11-05 1979-05-15 Bayer Aktiengesellschaft 2,6-Dimethyl-3-carboxymethoxy-4-(2-nitrophenyl)-5-carbisobutoxy-1,4-dihydropyridine
DE2650013C3 (de) * 1976-10-30 1981-04-02 Bayer Ag, 5090 Leverkusen 1.4-Dihydro-2.6-dimethyl-4-(3-nitrophenyl)-3.5-pyridindicarbonsäureisopropyl-(2-propoxy-äthyl)-ester, Verfahren zu seiner Herstellung sowie ihn enthaltende Arzneimittel
DE2815578C2 (de) * 1978-04-11 1986-01-16 Bayer Ag, 5090 Leverkusen Neue pharmazeutische Verwendung von Nimodipin
DE2841667A1 (de) * 1978-09-25 1980-04-10 Bayer Ag Fluorhaltige 1,4-dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel

Also Published As

Publication number Publication date
AU2758384A (en) 1984-11-08
EP0126315A1 (de) 1984-11-28
DK224184D0 (da) 1984-05-04
ATE24835T1 (de) 1987-01-15
KR920000306B1 (ko) 1992-01-11
ES8505542A1 (es) 1985-06-01
FR2545354B1 (fr) 1986-09-26
PT78542B (en) 1986-07-14
DE3316510A1 (de) 1984-11-08
JPH0422888B2 (cg-RX-API-DMAC7.html) 1992-04-20
EP0126315B1 (de) 1987-01-14
GR81609B (cg-RX-API-DMAC7.html) 1984-12-11
HK75889A (en) 1989-09-29
IL71744A (en) 1988-04-29
BE899564A (fr) 1984-11-05
JPS59206305A (ja) 1984-11-22
SG44489G (en) 1989-11-17
US5114956A (en) 1992-05-19
KR840009031A (ko) 1984-12-24
IT8448139A0 (it) 1984-05-04
DE3461988D1 (en) 1987-02-19
IT1181804B (it) 1987-09-30
DK164148C (da) 1992-10-26
AU562293B2 (en) 1987-06-04
FR2545354A1 (fr) 1984-11-09
DK224184A (da) 1984-11-07
ZA843352B (en) 1984-12-24
ES531995A0 (es) 1985-06-01
IL71744A0 (en) 1984-09-30
IT8448139A1 (it) 1985-11-04
PT78542A (en) 1984-06-01
DK164148B (da) 1992-05-18

Similar Documents

Publication Publication Date Title
US5114956A (en) Parenteral formulation of nimodipine
US4971079A (en) Pharmaceutical preparation possessing antinicotine effect and method of producing same in a gum carrier
US5061714A (en) Isoquinoline composition for the treatment of glaucoma or ocular hypertension
US4444758A (en) Nonapeptide for treating addictive drug withdrawal conditions
AU4583893A (en) Injection and injection kit containing omeprazole and its analogs
DE69033915D1 (de) Xanthinderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Anwendung
JPS62242618A (ja) 水銀含有防腐剤を安定化した眼炎治療薬
DE60022789T2 (de) Zusammensetzung die substituierte benzimidazole enthält
US4590207A (en) Therapeutic and/or preventive ophthalmic solution for intraocular hypertension and glaucoma
EP0908176B1 (de) Intravenöse Applikationsform von Thalidomid zur Therapie Immunologischer Erkrankungen
EP0288969B1 (en) Antiulcer composition
EP0191792B1 (de) Prostacyclin-derivate mit zytoprotektiver wirkung an der niere
DK167559B1 (da) Buprenorphinholdigt farmaceutisk suppositorium
CA2087147A1 (en) Method for administration of azauridine for the treatment of rheumatoid arthritis
DE69423529T2 (de) Arzneizusammensetzungen enthaltend Argatrobananaloge
FI104071B1 (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 2,5-dihydro-2,5-diokso-1H-bents[b]atsepiinijohdannaisten valmistamiseksi
US4399129A (en) Treating shock
WO1991015202A1 (de) Pharmazeutische wässrige lösung von 4-[2-(benzolsulfonylamino)-ethyl]-phenoxyessigsäure
EP0706395A1 (en) Use of ropivacaine in the manufacture of a pharmaceutical with analgetic effect with minimal motor blockade
US4829068A (en) Treatment of disorders of the gastro-intestinal tract
EP0317624B1 (en) Thyrotropin-releasing hormone analogs in cns injury
WO1982002041A1 (en) Method for providing long-lasting local anesthesia and compounds and compositions therefore
US3856963A (en) Use of injectable compositions of the ({30 )-optional isomer of the alpha racemate of 2-(2-ethyl-2-phenyl-1,3-dioxolan-4-yl) piperidine to control pain
US5622709A (en) Cimetidine-phenol pharmaceutical composition
DE345883T1 (de) Verwendung von dapiprazol zur herstellung eines arzneimittels zur verhinderung des toleranzentwicklung bei der analgetischen behandlung mit morphin.

Legal Events

Date Code Title Description
MKEX Expiry